Neoadjuvant Immunotherapy Produces Promising Antitumor Response in Locally Advanced dMMR/MSI-H CRC
July 25th 2022Patients with mismatch repair deficient and/or microsatellite instability–high locally advanced colorectal cancer appear to derive promising benefit from treatment with neoadjuvant immune checkpoint inhibitors.
Hope S. Rugo, MD, on Comparing CDK4/6 Inhibitors in HR+/HER2– Advanced Breast Cancer
July 24th 2022Hope S. Rugo, MD, FASCO, reviewed data from a matching-adjusted indirect comparison study which analyzed quality of life in patients with hormone receptor–positive, HER2-negative advanced breast cancer treated with ribociclib- or abemaciclib-based regimens.
Roger Li, MD, Talks Future Analyses of CG0070 Plus Pembrolizumab in BCG-Unresponsive NMIBC
July 23rd 2022Roger Li, MD, spoke about future trials planned for the combination of CG0070 plus pembrolizumab for patients with non–muscle invasive bladder cancer who were unresponsive to bacillus Calmette-Guerin.
ddPCR Analysis Effective in Identifying POLE Mutations in Endometrial Cancer, Study Finds
July 22nd 2022Investigators recommended that ddPCR testing and immunohistochemical staining be used to detect POLE status and p53/mismatch repair status, respectively, and allow for more rapid classification and risk-stratification.
Pembrolizumab, CRT Combo Misses EFS End Point in Unresected Locally Advanced HNSCC
July 22nd 2022The phase 3 KEYNOTE-412 trial assessing pembrolizumab and consolidation chemoradiotherapy plus maintenance pembrolizumab in unresected locally advanced head and neck squamous cell carcinoma missed its primary end point of event-free survival improvement vs matched placebo.
FDA Grants Fast Track and Rare Pediatric Disease Designation to WU-CART-007 in R/R T-Cell ALL/LBL
July 20th 2022WU-CART-007 was granted fast track and rare pediatric disease designation by the FDA for the treatment of patients with relapsed/refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
Carfilzomib Appears Safe, Efficacious in Japanese Patients With Relapsed/Refractory Multiple Myeloma
July 20th 2022Post-marketing surveillance data further confirmed carfilzomib to be a well-tolerated and promising option among patients with relapsed/refractory multiple myeloma, although investigators emphasize the importance of watching for cardiac comorbidities.
Medicaid Associated With Reduction in Racial/Ethnic Disparities in De Novo Stage IV Breast Cancer
July 19th 2022Investigators reported a reduction in racial and ethnic disparities among patients with de novo stage IV breast cancer following implementation of Medicaid expansion, and included a decreased risk of death for patients in a racial/ethnic minority compared with White patients.
Atezolizumab Plus Bevacizumab Induces Promising Clinical Responses in Neuroendocrine Tumors
July 19th 2022Patients with pancreatic and extrapancreatic neuroendocrine tumors treated with atezolizumab plus bevacizumab experienced consistent clinical responses and a progression-free survival consistent with other therapies.